itolizumab
itolizumab: sourced relationships with 1 company · 1 clinical trial tracked.
itolizumab evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could itolizumab → EQ affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Equillium, Inc. (EQ) Graft Versus Host Disease | Phase 3 |
Clinical Trial Registry Records (1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Primary endpoint: The efficacy of itolizumab versus placebo as initial therapy for aGVHD in combination with corticosteroids in achieving early disease response.
Frequently asked questions
Which companies have sourced relationships with itolizumab?
itolizumab has dated SEC/FDA relationship records for Equillium, Inc..
How many clinical trials involve itolizumab?
BioSniper tracks 1 clinical trial involving itolizumab.